long-term momelotinib exposure in jaki-naïve or previously jaki-treated myelofibrosis patients
Published 3 years ago • 100 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
1:40
momelotinib for the treatment of myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
14:38
hematology in 10 min hemostasis and coagulation mp4 final
-
3:19
first-line treatment selection in myelofibrosis
-
4:25
update on momelotinib for myelofibrosis
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
1:01
latest advances in myelofibrosis treatment
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
3:12
transfusion independence and momelotinib in myelofibrosis
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
2:03
unmet needs in immune thrombocytopenia